US LNG exports surge but will buyers in China turn up?
AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of nearly $240 billion, has announced that its 2025 Annual General Meeting (AGM) will be held on Friday, April 11, 2025, at 2:30 p.m. British Summer Time (BST). The AGM will be digitally enabled, allowing shareholders to participate remotely.
The pharmaceutical giant, known for its portfolio of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, confirmed in a recent filing with the Securities and Exchange Commission that the notice and proxy form for the AGM are now publicly accessible and have been submitted to the National Storage Mechanism. According to InvestingPro data, AstraZeneca (NASDAQ:AZN) has demonstrated robust performance with annual revenue of $54.07 billion and impressive revenue growth of 18% in the last twelve months. Shareholders can find the AGM documents on the company’s website.
The agenda for the upcoming AGM includes routine corporate matters such as the receipt of the company’s accounts and reports for the year ended December 31, 2024, confirmation of the 2024 interim dividends, and the re-appointment of PricewaterhouseCoopers LLP as the company’s auditor. Additionally, shareholders will vote on the authorization for directors to allot shares and disapply pre-emption rights, as well as the potential purchase of the company’s own shares.
AstraZeneca has also proposed to reduce the notice period for general meetings, a move that requires shareholder approval. The company has outlined the rights of ordinary shareholders concerning attendance and voting, specifying the record dates for different categories of shareholders, including those holding American Depositary Receipts.
This SEC filing serves as the formal notice for AstraZeneca’s AGM, ensuring shareholders are informed of their rights and the matters to be addressed. The company, headquartered in Cambridge, UK, emphasizes its commitment to innovative medicine, with its products reaching patients in over 125 countries. InvestingPro analysis indicates the company maintains a "GREAT" financial health score and has consistently paid dividends for 33 consecutive years. For detailed insights and access to the comprehensive Pro Research Report covering AstraZeneca’s financial metrics, valuation, and growth prospects, investors can visit InvestingPro.
The information for this article is based on a press release statement.
In other recent news, AstraZeneca has reported positive results from its MATTERHORN Phase III trial, which evaluated the use of Imfinzi (durvalumab) in combination with standard chemotherapy for treating early-stage gastric and gastroesophageal junction cancers. The trial showed a statistically significant improvement in event-free survival for patients receiving the Imfinzi-based regimen compared to chemotherapy alone. This marks a significant development in the treatment of gastric cancer, which is the fifth leading cause of cancer death worldwide. Additionally, AstraZeneca disclosed that top executives, including CEO Pascal Soriot and CFO Aradhana Sarin, have acquired shares following the vesting of a deferred bonus plan. The transactions, conducted outside a trading venue, involved shares that vested after a three-year holding period. Furthermore, AstraZeneca announced its total number of voting rights as of the end of February, confirming that the company holds no shares in Treasury. These developments reflect AstraZeneca’s ongoing commitment to transparency in its corporate governance practices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.